JPMorgan CEO Jamie Dimon expressed concern about inflation and predicts higher interest rates for longer than expected. He highlighted secular drivers such as the energy transition, geopolitical is...

Biotech is one of the most exciting industries to invest in right now. Companies have drugs on the market worth billions and continue to strive to produce the newest and best treatments in modern m...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

-    AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammato...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?

AbbVie, Inc. (NYSE:ABBV ) Bank of America Health Care Conference Call May 15, 2024 1:40 PM ET Company Participants Robert Michael - CEO Roopal Thakkar - SVP, Chief Medical Officer, Global Therapeut...

2 Fortune 100 Best Co's To Work For Are Also Good To Own

AbbVie (ABBV) inks an option-to-license and collaboration deal with Gilgamesh to develop next-generation therapies for psychiatric disorders.

AbbVie's best-selling product recently lost its patent protection, threatening the company's future results. The drugmaker's R&D pipeline, however, is more promising than it's getting credit for.

Novo Nordisk's Ozempic has changed the business entirely. Eli Lilly is a diversified giant with GLP-1 tailwinds.

AbbVie is a diversified healthcare company that has been able to strengthen its portfolio via acquisitions. AT&T has faced a lot of negative press in recent years but its fundamentals remain sound.

Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.

Shares of AbbVie NYSE: ABBV fell hard in the wake of its Q1 earnings report, but the dip is over. The market response to slowing Humira sales is overshadowed by strength in the non-Humira portfolio...

NORTH CHICAGO, Ill. , May 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024.

AbbVie's revenue grew slightly in the first quarter despite Humira losing steam. The company's successors to Humira are proving worthy.